Upadacitinib联合生物制剂治疗难治性克罗恩病的病例系列
该描述性病例系列纳入27例难治性克罗恩病患者,接受Upadacitinib联合Infliximab、Risankizumab、Ustekinumab或Vedolizumab治疗。12周时24例达临床应答、9例达无激素缓解;52周时分别为15/20和11/20。联合治疗显示有效且安全,需前瞻性研究验证。
要点
- 联合治疗12周临床应答24/27,无激素缓解9/27。
- 52周时临床应答15/20,无激素缓解11/20。
- 不良事件13例,3例因此停药。
核心结论
- Upadacitinib联合生物制剂对难治性克罗恩病可能有效且安全,需前瞻性研究进一步验证。
研究设计与样本
- 描述性病例系列,纳入27例难治性克罗恩病患者,联合方案包括Upadacitinib联合Infliximab(n=1)、Risankizumab(n=17)、Ustekinumab(n=3)或Vedolizumab(n=6)。
主要发现
- 12周时24例达临床应答,9例达无激素缓解。
- 52周时20例中15例达临床应答,11例达无激素缓解。
- 内镜应答和肠外表现改善常见。
- 13例发生不良事件,3例因不良事件停药。
临床怎么用
- 对难治性克罗恩病可考虑Upadacitinib联合生物制剂,但需密切监测不良事件。
局限性
- 为描述性病例系列,样本量小,缺乏对照,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission. At 52 weeks, these rates were 15/20 and 11/20, respectively. Endoscopic response and extraintestinal manifestation improvement were frequently observed. Adverse events occurred in 13 patients, leading to treatment discontinuation in three. Combining upadacitinib with a biologic appeared effective and safe, warranting further investigation in prospective studies.
引用
- Dalal RS, Clarke LM, Cabral HJ, et al. Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series. Aliment Pharmacol Ther. 2025. PMID: 40916681. doi:10.1111/apt.70298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。